A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

NCT04457310 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Early Course Schizophrenia Spectrum Disorder

Interventions

DRUG: CVL-562 (PF-06412562) 1 mg
DRUG: CVL-562 (PF-06412562) 4 mg
DRUG: CVL-562 (PF-06412562) 15 mg
DRUG: CVL-562 (PF-06412562) 25 mg
OTHER: Placebo

Sponsor

Yale University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]